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Abstract
Genome sequences of Plasmodium falciparum allow for global analysis of drug responses to antimalarial agents. It was of
interest to learn how DNA microarrays may be used to study drug action in malaria parasites. In one large, tightly controlled
study involving 123 microarray hybridizations between cDNA from isogenic drug-sensitive and drug-resistant parasites, a
lethal antifolate (WR99210) failed to over-produce RNA for the genetically proven principal target, dihydrofolate reductase-
thymidylate synthase (DHFR-TS). This transcriptional rigidity carried over to metabolically related RNA encoding folate and
pyrimidine biosynthesis, as well as to the rest of the parasite genome. No genes were reproducibly up-regulated by more
than 2-fold until 24 h after initial drug exposure, even though clonal viability decreased by 50% within 6 h. We predicted
and showed that while the parasites do not mount protective transcriptional responses to antifolates in real time, P.
falciparum cells transfected with human DHFR gene, and adapted to long-term WR99210 exposure, adjusted the hard-wired
transcriptome itself to thrive in the presence of the drug. A system-wide incapacity for changing RNA levels in response to
specific metabolic perturbations may contribute to selective vulnerabilities of Plasmodium falciparum to lethal
antimetabolites. In addition, such regulation affects how DNA microarrays are used to understand the mode of action of
antimetabolites.
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Introduction
Malaria parasites infect over 300 million people around the
world and the most virulent species, Plasmodium falciparum, kills 1–2
million individuals per year [1–3]. The availability of genome-
wide DNA microarrays for P. falciparum, has facilitated insights into
many complex biological problems. During erythrocytic develop-
ment, over 3,000 genes are expressed in a cascade of simple,
mostly unique, sigmoidal patterns [4–7]. While some genes are
expressed at a steady rate, hundreds of genes show at least 30-fold
change in expression during the erythrocytic cycle [4]. In addition
DNA microarrays have been used to understand stage-specific
differentiation [8–10], to determine invasion preferences [11,12],
and possibly pathogenesis [13–16].
At first, it was expected that DNA microarrays would also
permit a quick, unbiased look at the mode of action of antimalarial
drugs, particularly simple antimetabolites [17]. An underlying
premise was that parasites would sense metabolic perturbations
from a drug and make compensatory changes in its transcriptome
to adjust for the perturbations. Indeed, studies in other organisms
have demonstrated the value of such approaches. In Saccharomyces
cerevisiae, Mycobacterium tuberculosis, Candida albicans, mammalian cells
and even plants, specific antimetabolites up-regulated dozens of
target-related RNA by greater than 10-fold [18–23]. In many of
these systems confidence in the power of DNA microarrays to
reveal mechanisms of drug action come from perturbation of well-
understood metabolic pathways.
Our early preliminary studies had suggested that RNA levels for
metabolic targets in malaria parasites are not sensitive to lethal
antifolates nor to resulting specific metabolic perturbations [24–
27]. Here, in a complete, carefully controlled microarray study, we
definitively demonstrate that global gene expression in malaria
parasites is regulated in a fundamentally different way from model
organisms such as E. coli and yeast. Parasite transcription for
intermediary metabolism is hard-wired and not responsive to
specific, lethal, metabolic perturbations. We further demonstrate
PLoS Pathogens | www.plospathogens.org 1 November 2008 | Volume 4 | Issue 11 | e1000214that candidate pathways involved in drug-induced death may still
be identified through unconventional strategies, including probing
for subtle RNA changes with a large number of replicates and
tracking alterations in the hard-wired transcription program itself.
Results
A defined experimental system
To guard against broad pleotropic transcriptional effects that
may be difficult to interpret in drug-treated parasites, our study
exploits the potency and specificity of the antifolate WR99210
against P. faciparum (Structure, Figure S1). The parasite clone Dd2
fails to proliferate when exposed to 10 nM WR99210 for 48 h
[25,28–30]. A concentration of 10 nM was selected because it is
enough to kill all sensitive Dd2 cells (EC50=0.1 nM). Biochemical
assays and genetic complementation studies (using human DHFR)
have established P. falciparum DHFR-TS as the major target of
WR99210 [25,28–30].
To identify transcriptional changes that were directly related to
death events caused by the lethal effects of WR99210 on DHFR,
the present battery of microarray hybridizations included a control
WR99210-resistant cell-line, B1G9, which harbors a single
integrated copy of human DHFR in a Dd2 background [25,29].
B1G9 is resistant to as much as 500 nM WR99210.
Finally, to help frame drug-induced changes in RNA levels in
the context of cell physiology, Dd2 and B1G9 parasite lines were
exposed to 10 nM WR99210 for varying time periods and the
effects assessed with respect to clonal cell viability, continued
synthesis of nucleic acids, RNA levels for individual genes coding
for the effected pathways, and the global transcriptome.
Robust metabolism and development
A comparison of biochemical changes, morphological alter-
ations and loss of cell viability in WR99210-treated Dd2 provided
the first indication that malaria parasites resisted broad metabolic
or developmental arrests in response to specific lethal perturba-
tions. Using clonal viability as a measure of drug-induced death
[31], 50% of P. falciparum trophozoites became less viable after as
little as 6 h of exposure to 10 nM WR99210 (p,0.01) and
practically all parasite cells were non-viable after 12 h of drug
exposure (Figure 1A). However, even after 24 h of WR99210
treatment, trophozoites continued to follow a preordained
metabolic program for converting short pulses of radioactive
hypoxanthine into DNA, albeit with a lower amplitude (Figure 1B).
Microscopic examination of WR99210-treated trophozoite forms
of the parasite failed to show morphological changes until about
24 h after treatment when the schizonts appeared unhealthy
(Figure 1C). At subsequent hours, control cells released merozoites
and generated healthy rings but the WR99210-treated parasites
remained as ill schizonts. In parallel assays, WR99210-resistant
B1G9 cells behaved like untreated Dd2 (data not shown).
Tracking genome-wide changes
In a single large controlled experiment, Plasmodium transcrip-
tome changes were followed in WR99210-treated parasites using
DNA microarrays with 7,685 oligonucleotide probes per slide,
representing all open reading frames in the genome [4,17]. For
added value and confidence, the custom array also carried multiple
probes per gene for key enzymes in the target pathway of folate and
pyrimidine metabolism (Table S1 and S3). RNA samples from
synchronized Dd2 and B1G9 trophozoites, that had been treated
with 10 nM WR99210 for varying durations, were hybridized
against a common pool of trophozoite RNA from a cognate clone
(Figure 2A). For each time point, samples from biological
duplicates were hybridized to four microarray slides, including
dye exchanges. The biological duplicates were from independently
propagated cultures to minimize misleading, stochastic variations
in gene expression for surface proteins ([32], Figure S2 and Figure
S3 for description of data normalization and variation between
technical and biological variability). In total, the present
normalized data is derived from 123 microarray hybridizations.
As discussed below, this redundancy and accuracy was necessary
to interpret some small but informative perturbations in RNA in P.
falciparum. For some genes, it was possible to detect as little as 10–
20% changes in RNA levels, with statistically significant
reproducibility. Details of the experimental design, raw output,
and statistical analysis are presented in MIAME-compliant format
to the NIH-based GEO database (Accession # GSE9724 for
WR99210 data from Seattle and # GSE9853 and # GSE9868 for
the pyrimethamine data from Bangkok).
‘‘Unresponsive’’ target pathways
During normal 48-hour developmental changes in erythrocytes,
RNA levels for individual enzymes for pyrimidine and folate
biosynthesis change nearly 10-fold [4]. During continual WR99210
treatment for 24 h, malaria parasites showed very little deviation in
their transcriptome, even as they died from antifolate treatment.
First, expression of DHFR-TS, the immediate target of
antifolates was examined in detail. Fluorescently labeled cDNA,
generated from WR99210-treated and non-treated cells, was
hybridized to 12 unique oligonucleotides derived from different
parts of the 1,863 bp DHFR-TS coding strand (Figure 2A and
2B). Regardless of the WR99210-susceptibility status of the
parasite clone, and regardless of whether the cells were treated
with solvent or the antifolate, hybridization of fluorescent cDNA to
most probes for DHFR-TS did not increase (and actually
decreased slightly) during the 24 h normal progression of
trophozoites to schizonts, (Figure 2D). Based on combined data
from all 12 probes, RNA coding for DHFR-TS did not increase by
more than 20% at any time point after WR99210-treatment
(Figure 2C). This microarray-based analysis of DHFR-TS is
Author Summary
Traditional knowledge of gene regulation, learned largely
from non-pathogenic model organisms such as E. coli,
yeast, and mice, suggests that RNA for metabolic pathways
are regulated in large part by DNA-binding transcriptional
factors that are responsive to cellular metabolic needs. We
demonstrate that the malaria-causing Plasmodium falci-
parum parasites, under lethal drug pressure from an
antifolate with a known mechanism of action, are
incapable of large reproducible changes in RNA levels for
the target pathways, or for any other gene throughout the
genome. Small RNA changes, possibly informative of
perturbed pathways, can be detected in dying parasites.
In addition, significant RNA changes are seen when the
hard-wired program, governing RNA levels, itself is altered.
Our data formally proves that RNA levels for intermediary
metabolism in malaria parasites are largely predetermined.
We propose that as a parasite with a complex life cycle
travels from one largely predictable intracellular biochem-
ical environment to another, such hard-wiring may be
sufficient to manage transcript levels for intermediary
metabolism without employing sensory functions. Such a
system-wide host–parasite difference in gene regulation
may create unexpected pharmacological opportunities
when important target pathways are rigid in the parasite
but dynamically regulated in host cells.
Robust RNA in Dying Malaria Parasites
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tion Assays (RPA) [25] and qRT-PCR [33]. For additional
certainty, given recent description of differential expression of
small regulatory RNA within the coding region of mammalian
DHFR [34,35], we undertook an independent detailed analysis of
DHFR-TS expression using qRT-PCR spanning twelve different
parts of the DHFR-TS coding region. As seen with the different
unique oligonucleotide microarray probes (Figure 2D), qRT-PCR
(Figure 2E–F) unambiguously confirmed that DHFR-TS RNA, or
parts of DHFR-TS RNA, were not overproduced at protective
levels in parasites treated with the lethal antimetabolite WR99210.
Since the 10 nM WR99210 treatment was at 100-times the EC50
for Dd2 (0.1 nM), complete protection through increases in target
RNA levels would require at least 100-fold increases in DHFR-TS
RNA. Even a 10% protection from a RNA-based mechanism
would require at least a 10-fold increase in DHFR-TS RNA.
Second, in addition to DHFR-TS, the expression of fourteen
additional enzymes in the folate and pyrimidine biosynthesis
pathways also did not deviate significantly from their normal
transcriptional patterns. This analysis was based on at least two
different microarray probes for each of the enzymes listed in Figure 3.
The only two RNA species that showed small, consistent, significant
changes from their normal expression program were serine
hydroxymethyltransferase (SHMT) and a ribonucleotide reductase
small subunit gene (RNR2). However, even these two responsive
RNA species showed, at most, only a 2-fold change at very late time
points(maximum 105%increaseat 24 h,p,0 .0 0 2 ) .Ev e nt h o u g ht h e
methylenetetrahydrofolate-using thymidylate synthase is thought to
be the ultimate target of DHFR inhibition, the unresponsiveness of
pyrimidine biosynthesis to DHFR-TS inhibitor have not previously
been reported. Just as our preliminary microarray data had reported
[24,26,27], a qRT-PCR study from an independent group has also
shown that RNA for folate-biosynthesisenzymes are not up-regulated
in response to pyrimethamine-treatment [33]. This other study did
not look at changes in RNR2 and did not pickup the subtle drug-
dependent alterations in transcripts for SHMT that are seen with the
current large microarray data set.
‘‘Unresponsive’’ genome
Given the inability of P. falciparum transcriptional program to
overproduce RNA for DHFR-TS and related enzymes after
antifolate treatment, we wanted to understand the extent of the
overalltranscriptionalobstinacyindrug-sensitiveparasites.Inthefirst
3 h after WR99210 treatment, when death events were underway
(p,0.05, Figure 1A), no genes showed statistically significant
deviations from their normal developmental program that was
greater than 2-fold in expression. Even 24 h after WR99210-
treatment, when all cells are completely committed to die, greater
than 99% of the genes in the Plasmodium transcriptomedid not deviate
significantly in gene expression.
Death-related ‘‘RNA whispers’’
By exploiting our experimental design, which included side-by-
side treatment of isogenic sensitive and resistant malaria parasite
Figure 1. The antifolate WR99210 rapidly triggers commitment to death but fails to shut down metabolism or development. While
10 nM WR99210 is sufficient to commit 50% of the cells to lethality within 6 h, the parasites continue to obey normal metabolic pattern for
hypoxanthine uptake and incorporation into DNA (albeit at a lower amplitude) and continue to develop to schizogony for upto 24 h. (A) Rapid
decrease in clonal viability of WR99210 exposed Dd2 cells. Trophozoite forms of infected erythrocytes in 10 ml cultures were exposed to 10 nM
WR99210 for varying periods. Washed cells were diluted and plated in 96-well plates (see methods). Control diluted cells revealed about 20 positive
colonies starting at 12–16 days. (B) Continued incorporation of hypoxanthine in WR99210-treated cells. Young trophozoite forms of infected
erythrocytes in 10 ml cultures were exposed to 10 nM WR99210 for varying periods. Cells were pulsed directly with radioactive hypoxanthine for 1 h.
Incorporation of radioactive hypoxanthine into DNA was measured by precipitation of nucleic acids on glass fiber filters. Maximum incorporations
was seen at 4–8 h into trophozoite development.N; Solvent-treated cells, &; WR99210-treated cells. (C) Synchronized Dd2 cells at early trophozoite
stage were treated with 10 nM WR99210 or 0.1% DMSO (control) for 48 h. Parasites were visualized by light microscopy of Giemsa-stained blood
smears. Images at 6 h, 12 h, 24 h, and 30 h of WR99210 treatment are shown. Based on microscopy, the parasites followed normal development up
to about 24 h after WR99210 treatment.
doi:10.1371/journal.ppat.1000214.g001
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possible to detect small reproducible changes in RNA in dying
cells and only in dying cells.
Figure 2. RNA for the antifolate target dihydrofolate reduc-
tase-thymidylate synthase is not overexpressed in WR99210-
treated cells. Using multiple probes for DNA microarrays, as well as
multiple primer sets to amplify different regions of the DHFR-TS cDNA
by qRT-PCR, it is shown that mRNA for DHFR-TS is not overexpressed in
protective amounts after antifolate treatment. Note that the microarray
data color bar has been set at high sensitivity to pick up any small but
significant and reproducible changes in expression. (A) Design of the
DNA microarray experiment. This simple scheme was repeated twice for
each combination of treatments (WR99210 or DMSO solvent) and
varying parasite clones (Dd2 vs B1G9) in Seattle. Young trophozoites
were split into treated cells (3 h to 24 h), and untreated cells (0 h). After
WR99210 treatment at 10 nM concentrations for various durations, RNA
was extracted, converted to cDNA, fluorescently labeled, and hybridized
against RNA from pooled reference untreated cells (0 h). One,
duplicates from the same biological samples were run with dye
inversion. Two, the exact scheme was repeated with independently
grown parasites, thus generating 4 hybridizations per time point of
WR99210 treatment. This scheme was labeled SD, for Sensitive cells
treated with the drug analog WR99210. Finally, the whole scheme of
duplicates, was repeated 3 more times (Sensitive clone Dd2 with Solvent
(SS), Resistant clone B1G9 with the drug analog WR99210 (RD), and
Resistant clone B1G9 with Solvent (RS). Altogether this resulted in
microarray data generated from over 123 slides, each carrying about
7,685 oligonucleotide probes. Details of the large experiment are
presented in the Methods section. (B) Illustration of regions of DHFR-TS
gene queried with oligonucleotide probes (black plus blue boxes) and
qRT-PCR primers (black boxes) to measure DHFR-TS mRNA levels in
parasites treated with the antifolate WR99210. The DNA sequences
corresponding to the 12 unique microarray oligonucleotide probes for
DHFR-TS are presented in Table S1. The DNA sequences for the primers
used for DHFR-TS qRT-PCR are presented in Table S2. (C) WR99210-
treated sensitive cells do not increase DHFR-TS RNA to high levels, as
judged by DNA microarrays data that was collected and averaged from
12 different, unique DNA microarray probes representing different parts
of the complete DHFR-TS coding region (see Figure 3B). Hybridization
of fluorescent cDNA samples originating from parasites treated with
WR99210 for various times (red fluorescence) were compared to non-
treated parasites (green fluorescence) and represented as R/G ratios on
a log2 scale: A black box signifies no change in expression compared to
starting trophozoites, a red box represents some over-expression and a
green box designates a decrease in DHFR-TS RNA, compared to starting
trophozoites (time 0 h). Missing data is shown as gray. Each bar (SD, SS,
RD, and RS) represents different combinations of cell clones (S or R) and
treatment (D or S), starting from 3 h to 24 h of treatment. (D) Individual
DHFR-TS probes revealed no significant differences in RNA levels from
within the DHFR-TS coding region. (E) WR99210-treated sensitive cells
do not increase DHFR-TS RNA to high levels as judged by qRT-PCR (3–
24 h treatment). To independently measure the magnitude of DHFR-TS
RNA levels in antifolate treated Dd2 cells, qRT-PCR was applied to 4
different regions of the DHFR-TS coding mRNA sequence. The primer
pairs from around nucleotide 13, 135, 1409, and 1542 of the coding
region, confirmed that during the 24 h maturation of DHFR-TS, solvent-
treated parasites showed a gradual decrease in DHFR-TS RNA.
Furthermore, while the qRT-PCR revealed a slightly higher level of
DHFR-TS RNA in WR99210-treated Dd2 cells at 24 h, this was not due to
an increase over the RNA present before initiation of drug treatment.
DHFR-TS mRNA level are represented for solvent-treated cells at 9 h and
15 h (gray bar), for solvent-treated cells at 24 h (light-green bar), for
WR99210-treated cells at 9 h and 15 h (black bar), and for WR99210-
treated cells at 24 h (dark-green bar). Data are shown as means6SEM.
(F) DHFR-TS RNA, probed across the whole coding region, failed to
show up-regulation in WR99210-treated Dd2 cells at 24 h. There was a
very small but consistent and significant failure to undergo normal
repression at 24 h. However, the failure to overexpress protective
quantities of DHFR-TS was consistent with the DNA microarray data.
DHFR-TS mRNA level in solvent-treated cells (light-green bar) and in
WR99210-treated cells (dark-green bar) are shown as means6SEM.
doi:10.1371/journal.ppat.1000214.g002
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PLoS Pathogens | www.plospathogens.org 4 November 2008 | Volume 4 | Issue 11 | e1000214Figure 3. As seen for DHFR-TS RNA levels, RNA for other enzymes in the folate and pyrimidine biosynthesis do not increase to high
levels in WR99210-treated sensitive-parasites, Dd2. DNA microarray data was examined, not just from the coding region of the known
antifolate target DHFR-TS (Figure 2), but also from the coding sequences for all the known enzymes of de novo pyrimidine and folate metabolism.
Each gene was probed with at least two unique oligonucleotide probes (see Table S3 for oligonucleotide sequences). As in Figure 2C, hybridization of
fluorescent cDNA originating from parasites treated with WR99210 for various times (red fluorescence) was compared to non-treated parasites (green
fluorescence) and represented as R/G ratios on a log2 scale: A black box signifies no change in expression compared to starting trophozoites, a red
box represents some over expression and a green box designates a decrease in DHFR-TS RNA, compared to starting trophozoites (time 0 h). Each bar
(SD, SS, RD, and RS) represents different combinations of cell clones (S or R) and treatment (D or S), starting from 3 h to 24 h of treatment.
doi:10.1371/journal.ppat.1000214.g003
Figure 4. Death-related up-regulated expression changes in WR99210-treated parasites. Genes whose expression changed in dying cells
but not in three other controls were identified. Expression levels were compared between SD and SS, SD and RD, and SD and RS at each time point.
Probes were selected against these three comparisons jointly, with multiple testing adjusted p,0.01. Thirty four genes showed a drug-dependent
increase in gene expression (Table S4 for PlasmoDB gene number).
doi:10.1371/journal.ppat.1000214.g004
Robust RNA in Dying Malaria Parasites
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whose expression levels increased at least at one time point during
the 24 h WR99210 study (Figure 4, and Table S4 for gene names,
gene ID numbers, and fold-changes). There were 21 genes whose
expression levels decreased at least at one time point (Figure 5 and
Table S5). These changes were considered antifolate death-related
genes (AFDG) because they were not seen in solvent-treated, drug-
sensitive Dd2 parasites, and were not seen in solvent-treated or
WR99210-treated resistant B1G9 cells.
The numerous death-related RNA changes were subtle and
probably not protective, but they were statistically significant and
possibly reflected larger physiologically important metabolic
perturbations in dying parasite cells. The death-related transcripts
provide the first insights into downstream events that may connect
inhibition of DHFR-TS by antifolates to ultimate loss of cell
viability (Table S4 and S5 for PlasmoDB gene numbers). Given
the known mechanism of action of antifolates, the presence of
ribonuceotide reductase and DNA repair endonuclease on this list
was satisfying. The intriguing presence of putative cell-signaling
proteins (phosphotyrosine phosphatase activator; a GTP binding
protein; a Rab18 GTPase; and a calcium-dependent protein
kinase) and some potential degradative enzymes (cysteine protease
SERA3; protease; 20S proteosome beta 4) on the list of death-
related genes should stimulate investigations of their possible role
in antifolate toxicity. The list of death-related genes also included
some known enzymes whose role in antifolate-mediated death is
not obvious but should also be of interest (inorganic pyrophos-
phatase; gamma-glutamylcysteine synthetase; elongation factor
Tu; and long-chain fatty acid ligase-oxalyl CoA decarboxylase).
Finally, this genome-wide analysis revealed that, of the 55
antifolate-triggered small transcript changes, there were 25
hypothetical gene products with no previous known functions in
other cell types.
Confirmation and cross-checks
To evaluate the validity and reliability of the small changes in
RNA levels detected in the DNA microarray experiments, two
different approaches were taken.
Conventional quantitative RT-PCR was used to compare RNA
expression in independently cultivated P. falciparum Dd2 cells,
before and after 10 nM WR99210 treatment for 24 h. This time
point was used because the most significant changes on the
microarray occurred after 24 h and the magnitude of the changes
approached the resolution limits of RT-PCR. Out of 3 randomly
chosen up-regulated genes, all 3 showed the expected small up-
regulation upon WR99210 treatment (Table 1). Out of 3
randomly chosen down-regulated genes, 2 showed down-regula-
tion as expected but one did not. Overall, we concluded that,
though small, most RNA ‘‘whispers’’ picked up by the DNA
microarrays were verifiable by qRT-PCR.
In a completely different approach, two partner labs from two
different parts of the world compared microarray data to
determine if antifolate-treated parasites shared some common
signatures in their transcriptome. Realistically, all the WR99210-
reponsive genes from the Seattle study were not expected to show
up in the Thailand study because the two groups were working
with independently printed arrays, different parasites strains (Dd2
vs TM4/8.2), different antifolates (WR99210 vs pyrimethamine),
and different treatment antifolate doses (99.9% vs 50% IC values).
Yet, some of the most relevant changes should be shared, given the
common mechanism of action of WR99210 and pyrimethamine.
Indeed, a genome-wide comparison of transcript differences in
antifolate-treated parasites versus solvent-treated parasites not only
revealed 4 genes that were up-regulated and 5 genes that were
down-regulated in concordance but the changes occurred at
approximately the same time after antifolate treatment (Figure 6).
In addition to some new proteins with no prior known functions,
Figure 5. Death-related down-regulated expression changes in WR99210-treated parasites. Genes whose expression changed in dying
cells but not in three other controls were identified. Expression levels were compared between SD and SS, SD and RD, and SD and RS at each time
point. Probes were selected against these three comparisons jointly, with multiple testing adjusted p,0.01. Twenty one genes showed a drug-
dependent decrease in gene expression (see Table S5 for PlasmoDB gene number).
doi:10.1371/journal.ppat.1000214.g005
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a ubiquitin-conjugating enzyme (PF10_0330). It is not clear why
the drug-induced down-regulation of RNA for the cytoadherance
linked protein CLAG2 (PFB0935w) [36,37] was seen in this set,
but it appeared consistently in all other measures of antifolate
toxicity in the present microarray study.
Altered hard-wiring
It was hypothesized that even if a genetically determined hard-
wired transcriptome is insensitive to real-time arrival of antime-
tabolites in the cell, perhaps the hard-wired program itself may
evolve to tolerate an antimetabolite, particularly if given a chance
to adapt over successive generations. Indeed, in the present large
experiment with multiple controls, it was possible to identify genes
whose expression in the resistant B1G9 cells was rewired in
concordance with protection against the drug WR99210 (Figure 7
and Figure S4).
In this most compelling gene set, expression in the drug-resistant
B1G9 cells behaved normally (as in non-treated, drug-sensitive
Dd2 cells) only when B1G9 cells were under WR99210 pressure (Figure 7
and Table S6). In other words, expression of these genes was
rewired so that it matched normal cells only when the antifolate
WR99210 was present. The expression pattern of these genes was
dissimilar in dying, drug-sensitive Dd2 cells exposed to WR99210,
or resistant B1G9 cells grown without WR99210 (Figure 7). This
data set included up-regulation of subtilisin-like protease 2
(PF11_0381) which might promote egress and reinvasion [38–
42], an ADP-ribosylation factor-like protein (PFI1005w) [43,44],
and several ‘‘hypothetical proteins’’. While detailed follow up
studies will clearly be needed, the alteration in subtilisin-like
protease expression ties nicely with morphological arrest of
WR99210-treated parasites as ill schizonts and failure to see
reinvasion and rings at later time points (Figure 1C).
A second set of permanent genetic alterations in the transcription
program involved genes whose expression in the resistant B1G9
cells was different from the WR99210 sensitive Dd2, regardless of
whether the antifolate was present or not (Figure S4 and Table S7).
While it is possible that these genes also contribute to antifolate
resistance mechanisms, this second data list should be accepted with
caution since at least some of the RNA changes may have arisen
throughadventitiouschanges inthecell line duetocollateralgenetic
damage during WR99210 adaptation.
Discussion
Many commonly accepted paradigms for designing selective
antimetabolites originate from the study of antifolates. Prior to the
availability of genome sequences, mechanisms of drug action and the
role of active site in selectivity were identified through intuitive
comparisons to normal metabolites [45] and validation through
resistance and transfection [46–48]. Our understanding of selective
and potent antimetabolites continues to improve: Low, fixed levels of
target enzyme in the parasite and the selective ability of host cells to
overexpress target enzymes can play an important role in drug
selectivity [25]. While useful, all such approaches have always relied
on existing knowledge of biochemistry, metabolism, and pharmacol-
ogy. Now, with the availability of genome sequences for Plasmodium
parasites [49–51], and accompanying tools such as DNA microarrays
[52,53], there is much enthusiasm about using open ended tools to
decipher drug action [17], particularly downstream biochemical and
cellular events that lead to cell death.
Table 1. qRT-PCR cross-check of representative microarray data.
Present label PlasmoDB ID Description Microarrays qRT-PCR
Ratio relative to time 0 SD/SS Ratio relative to time 0 SD/SS
SD24 SS24 SD24 SS24
AFDG-U13 PFD1120c membrane protein 3.42 1.03 3.31 2.82 0.98 2.89*
AFDG-U15 PF10_0330 ubiquitin-conjugating enzyme 2.70 1.14 2.37 3.18 0.82 3.89
AFDG-U28 PFC0710w inorganic pyrophosphatase 1.51 0.44 3.42 1.65 0.29 5.75
AFDG-D9 PFB0915w liver stage antigen 3 0.42 1.50 0.28 1.23 3.25 0.38
AFDG-D11 PFB0635w T-complex protein 1 0.68 2.01 0.34 1.70 1.46 1.17*
AFDG-D21 MAL6P1.231 lc fatty a ˆ CoA ligase/oxalyl CoA DC 0.90 3.77 0.24 0.86 1.95 0.44*
p-value of microarray data and half of qRT-PCR were ,0.05. * p,0.16.
doi:10.1371/journal.ppat.1000214.t001
Figure 6. Independent DNA microarray-based confirmation of
death-related expression changes in antifolate-treated para-
sites from two different labs. Early trophozoites (approximately
20 h post invasion) were treated with antifolates (10 nM WR99210 for
Dd2 and 0.5 mM pyrimethamine for TM4/8.2) for varying periods. RNA
was isolated and converted into labeled cDNA, and hybridized to a 70-
mer microarray as described in the Methods section. The expression
ratio of antifolate-treated to untreated control (SD/SS) at each time
point was plotted. WR99210 data at 3 h, 6 h, 9 h, and 24 h were
compared to pyrimethamine data at 2 h, 4 h, 8 h and 24 h.
doi:10.1371/journal.ppat.1000214.g006
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falciparum does not trigger overexpression of RNA for DHFR-TS,
the known target of the antifolate (Figure 2). Casual observation of
the microarray data clusters may suggest that DHFR-TS levels
increase slightly. However, the color representations can be
deceiving, in part because they are set at very high sensitivity
(Figure 2D). The actual DHFR-TS increases are neither large nor
statistically significant. While the follow up quantitative RT-PCR
(Figure 2E and 2F) did show slightly higher levels of DHFR-TS
RNA in treated cells, this was not due to RNA induction. The
small ‘‘increases’’ in DHFR-TS RNA level in WR99210-treated
Dd2 cells arise from a slight delays in normal degradation of
DHFR-TS RNA, mostly at very late time points in the dying cell.
When one asks the big question, do malaria parasites overexpress
the target DHFR-TS RNA to protective levels when treated with
the antifolate WR99210? The answer is clearly negative. Can
DNA microarrays be used to unambiguously assign mechanisms of
antifolate action through real-time changes in RNA levels after
drug exposure? The answer, again, is unambiguously negative.
Beyond the immediate target DHFR-TS, the parasites also do
not overproduce RNA for any of the enzymes of pyrimidine or
folate metabolism, two pathways known to be effected by
antifolates (Figure 3). Most importantly, long after P. falciparum
cells treated with WR99210 were committed to death, there were
no large consistent reliable increases in RNA for any of the genes
in the P. falciparum genome. The last observation shows that the
transcriptional obstinacy of P. falciparum is not just restricted to
folate biochemistry but permeates through much of the parasite’s
metabolic network involved in control of cell proliferation, and
eventually cell death. Since this large project started and has been
reported in preliminary form at scientific meetings, several other
smaller DNA microarray studies have also encountered transcrip-
tomes resistance to antimetabolites. This includes work on the
antimalarial choline analogue T4, the mitochondrial inhibitor
atovaquone, and most recently the polyamine biosynthesis
inhibitor DFMO [54–56]. Earlier claims that malaria parasites
show specific large transcriptional responses to chloroquine [57],
were reversed [58]. The later conclusion appears to be correct
since an independent study has also recently claimed a lack of real-
time changes in RNA levels in chloroquine-treated P. falciparum
[59]. Doxycycline a protein synthesis inhibitor for subcellular
organelles caused a whole-sale shutdown of apicoplast RNA, not
specific up-regulation of RNA for the target protein [60]. The
emerging general consensus is that malaria parasites do not mount
large increases in RNA in response to antimetabolites. Our
conclusions from the original discovery using antifolates remains
compelling because the study uses a potent, specific inhibitor
(WR99210) that targets a genetically validated target (DHFR):
Drugs with broad or poorly defined mechanism of action were
avoided because they can add to existing uncertainty about
malarial transcriptional responses.
Even though large protective changes in RNA were not seen in
drug-treated malaria parasites, the tightly controlled nature of the
present study led to unbiased glimpses into small, subtle
downstream RNA changes in drug treated malaria parasites.
One type of change involved small, reproducible real-time changes
in RNA in sensitive cells and only in the sensitive cells (Figure 3, 4
and 5). These include RNA coding for proteins involved in
relevant target pathways: ribonucleotide reductase of nucleotide
metabolism and serine hydroxymethyltransferase of folate metab-
olism. In addition, there were dozens of new genes whose
expression was perturbed and whose role in folate pharmacology
would be new and unexpected, including enzymes involved in
DNA replication, cell signaling, and protein turnover. Secondly,
while the hard-wired transcription for metabolic genes in malaria
parasites was largely unresponsive to drug-treatment in real-time,
the hard-wiring program itself could evolve in a population that is
under continual drug pressure. Such alterations in the transcrip-
tomes offer glimpses into new biochemistry related to drug action
(Figure 7). The last finding presents a clear caution to malaria
scientists who rely heavily on DNA transfections to study drug
action. Transfection of the malarial parasite line Dd2 with single
copy of the human DHFR originally proved the primary
mechanism of action of WR99210 [29]. However, emergence of
transformants always involve long delay phases, very similar to
those seen during in vitro selection for drug resistance in the
laboratory [61,62]. It is very likely that while human DHFR helps
confer resistance to WR99210, additional genetic changes in the
Figure 7. Adaptive changes in P. falciparum under long-term WR99210 exposure. Genes in resistant clone B1G9 under drug pressure (RD)
acted like sensitive clone Dd2 without drug pressure (SS). Expression levels of RS were compared with SS and RD (RS vs SS and RS vs RD) at
corresponding time points and correlation coefficient (r) were computed between SS and RD. Probes that met the criteria of p,0.01 for both
comparisons and r.0.85 were selected (Table S6 for PlasmoDB gene number).
doi:10.1371/journal.ppat.1000214.g007
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WR99210 tolerance and optimum growth in the transformed cell.
Identification of these secondary genetic changes are expected to
be fertile grounds for fully understanding downstream biochemical
changes that lead from DHFR-TS inhibition to cell toxicity.
The present findings add some general rules to help us
understand how some good antimalarial drugs work. First, as
gene amplification can contribute to drug resistance [63],
unconditional suppression of target protein and RNA for
metabolic enzymes may contribute to unusual vulnerabilities in
the parasite. Previously, P. falciparum DHFR-TS protein was shown
to bind its cognate RNA sequence differently than the host protein
[25]. Now we show that the production of RNA itself may be
severely limited and this repression of transcription is largely
insensitive to metabolic changes. Second, in principle, while
natural metabolites and their toxic homologues may not induce
large scale changes in target gene expression in malaria parasites,
it is conceivable that some other antimalarial molecules could
exhibit broad toxicity, in part, by misdirecting the hard-wired
transcriptional program of P. falciparum. Third, if there is limited
flexibility in regulating gene-expression, perturbations by drugs
must be balanced by compensating mutations affecting the
transcriptome [64]. This would influence frequencies of drug
resistance in unpredictable ways [62,65], as well as leave molecular
footprints of prior drug exposure throughout the genome [66,67].
The evolutionary implications of the hard-wired malaria
parasite transcriptome to control metabolism are significant.
Parasites appear to have at least two fundamentally different
strategies for gene regulation: Alterations in expression of genes for
surface proteins occur randomly to help parasites ‘‘outmaneuver’’
unpredictable immune responses from each new host the parasite
encounters [68–70]. In contrast, for intermediary metabolism, the
obligatory parasites seem to have evolved a deterministic
transcriptional program to match the defined and predictable
biochemical makeup of host cells. Compared to variations in
immune responses, the biochemical environment between differ-
ent host individuals probably does not vary significantly. The
biochemical adaptations which accompany these evolutionary
choices in gene regulation must be significant. A priori, the
systematic, sequential, rhythmic expression of metabolic genes in
malaria parasites must be determined by a sequential expression of
regulatory molecules which are largely insensitive to intracellular
levels of important metabolites. Of course, while such a model
could apply to repeated erythrocytic cycles, it need not preclude a
signal-based strategy for influencing differentiation of parasites.
Materials and Methods
DNA microarrays for P. falciparum
The present experiments used spotted DNA microarrays [71]
that were fabricated as previously described [9,32]. Commercially
available malaria oligonucleotides (Operon, version 1.1, https://
www.operon.com/arrays/oligosets_malaria.php) were combined
with in-house oligonucleotides representing P. falciparum genes in
folate and nucleic acid metabolism. The in-house oligos were
designed at the University of Washington using ArrayOligoSe-
lector [52] and synthesized by Operon Biotechnologies, Inc. The
arrays, each representing the majority of malarial open reading
frames plus the custom oligonucleotides, were printed on
polylysine-coated slides using an ultra fast, linear servo driven
DeRisi microarrayer. Slides were post-processed and hybridized
following the protocols as previously described (http://cmgm.
stanford.edu/pbrown/protocols/index.html). Each platform used
in the following experiments is described and can be accessed at
the NIH-based GEO database (Accession # GPL6187 for
WR99210 data from Seattle and # GPL6187 and # GPL6269
for the pyrimethamine data from Bangkok).
Parasites
At the University of Washington, Seattle, WA, P. falciparum
clones Dd2 and B1G9 were used for treatment with WR99210.
Clone Dd2 was derived from clone W2 from Southeast Asia and is
resistant to a variety of antimalarials, but not WR99210
[25,65,72]. The isogenic clone B1G9, which harbored a single
integrated copy of human DHFR in a Dd2 background, conferred
resistance to WR99210 and was kindly provided by Drs. David
Fidock and Thomas Wellems [25,29]. At the National Center for
Genetic Engineering and Biotechnology (BIOTEC), Bangkok,
Thailand, a pyrimethamine-sensitive laboratory clone TM4/8.2
was treated with pyrimethamine prior to microarray analysis. The
TM4/8.2 clone was obtained from Dr Sodsri Thaithong,
Chulalongkorn University, Thailand. At both sites, parasites were
cultured in vitro by standard methods [73].
Clonal viability
Clonal viability of WR99210-treated parasites was based on a
previously established assay [31]. Forty 10 ml cultures, with
synchronized early-trophozoite forms of infected erythrocytes,
were treated for different durations with 10 nM WR99210 in a
final concentration of 0.1% DMSO. Treatment times ranged from
3 h to 24 h, with two flasks per time-point. At appropriate times,
cells from each flask were washed and clonally diluted in drug-free
medium. Representative dilutions from each flask were plated at a
density of about one infected erythrocyte per well in 24 wells of a
96-well plate (4 samples per time point). Growth in each well was
monitored microscopically in drug-free medium for two to four
weeks. On average, 20 ‘‘colonies’’ (i.e. parasite containing wells)
were identified from solvent treated, time-zero parasite popula-
tions.
Rates of DNA metabolism
Trophozoite forms of infected erythrocytes in ten ml cultures
were incubated with 10 nM WR99210 for 1–24 h and then pulsed
with radioactive hypoxanthine (2 mCi per flask, 22 mCi/umol) for
one hour prior to collection of precipitable radioactive DNA on
glass fiber filters. In the absence of drug treatment, maximum
incorporation was seen at 4–10 h into trophozoite development
(approximately 5,000 cpm; 500 pmol/flask).
Drug treatment and RNA extraction
Overall, in Seattle, for the master DNA microarray experiment,
two large populations of Dd2 cells and two large populations of
B1G9 cells were prepared for treatment with WR99210. Dd2
clones, starting with about 100 infected erythrocytes per flask,
were setup in 60 flasks and propagated until 30 ml cultures were
established at 5% parasitemia, 2% hematocrit in each flask. These
independently propagated parasites were pooled and redistributed
into 60 flasks before drug treatment (see below). A second set of
biological replicates of Dd2 were propagated, pooled, and split
independently to give two truly independent populations of Dd2.
The overall goal was to neutralize stochastic changes in gene
expression for surface proteins [32]. This whole exercise was
repeated separately with clone B1G9.
To describe the details of the parasite preparation, in each set
above (each biological replicate of Dd2 or B1G9), parasites were
initially seeded in 10 ml cultures with about 100 infected
erythrocytes per flask. When parasitemia reached about 5%, the
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reached 5% in each 30 ml culture the first time, the infected cells
were synchronized with 5% sorbitol [74]. When parasitemia
reached 5% again, and when most of the infected erythrocytes
were in the ring stage, the synchronization was repeated once
more. These parasites (in one set) were pooled and redistributed
into 30 ml flasks, until they reached early trophozoite stage. Half
of these samples were saved as ‘‘Time zero, trophozoites’’ and
served as reference RNA for the time-course experiments. Of the
remaining parasites, half the 30 ml flasks were treated with 10 nM
WR99210 (1:1,000 dilution of 10 mM WR99210 stock in 100%
DMSO) and the other half were treated with solvent (final
concentration of 0.1% DMSO). At various time-points (3 h to
24 h), infected erythrocytes were centrifuged down, and parasites
were released by saponin treatment [75]. After two washes in PBS,
the parasites were resuspended in lysis buffer (RNAqueouse Kit,
Ambion) and RNA was isolated according to the manufacturer’s
instructions. As discussed above, 2 preparations of independently
derived Dd2 were treated with solvent or with 10 nM WR99210.
Similarly, 2 preparations of independently propagated B1G9 were
treated with DMSO solvent or with 10 nM WR99210.
In Thailand, for each treatment, three 30 ml culture plates
(90615 mm) of TM4/8.2 parasites were set up at 4% hematocrit
and 7–10% parasitemia. After two rounds of synchronization, an
early trophozoites culture (approximately at 18–20 h post
invasion) was treated with 0.5 mM pyrimethamine. The final
concentration of DMSO solvent in each treatment was 0.1%. A
culture containing 0.1% DMSO lacking drug was used as a
control. After 2 h, 4 h, 8 h and 24 h of drug exposure, parasites
were collected and extracted from erythrocytes by saponin lysis.
Total RNA was purified from parasite cells using Trizol reagent
(Invitrogen) according to the manufacturer’s instructions. Exper-
imental treatments were carried out from at least two independent
cultures to wash out stochastic biological variation.
For RT-PCR based confirmation experiments, appropriate
clones of independently seeded parasites were grown in 10 ml
cultures and RNA was collected by RNAqueouse Kit (Ambion)
according to the manufacturer’s instructions. Contaminating DNA
was removed from the total RNA samples using RQ1 RNase-Free
DNase (Promega).
Fluorescent cDNA preparation and hybridization
For each hybridization, 10 mg of total RNA was annealed with
5 mg pd(N)6 random primers (Amersham Biosciences Corp.) and
reverse transcribed to produce aminoallyl-dUTP (Sigma)-labelled
cDNA using StrataScript reverse transcriptase (Stratagene). Oligo-
(dT)21 primer was used instead of the random hexamer for
pyrimethamine treated samples from Thailand. The labelled
cDNAs were coupled with either monoreactive-Cy3 or -Cy5
(Amersham Biosciences) as previously described [32]. Purified
Cy3- and Cy5-labelled cDNAs were resuspended and mixed in
24 ml of hybridization solution containing 36 SSC, 0.2% SDS,
0.025 M HEPES and 0.75 mg/ml of poly A (Sigma) and
hybridized on a P. falciparum 70-mer microarray for 16 h at 63uC.
Data collection and analysis
After washing, slides were scanned in an Axon GenePix 4000B
microarray scanner and the intensity of spots was quantified using
GenePix Pro 3.0 Software (Axon Instruments, Inc.) as previously
described [32]. Briefly, during the gridding process, images were
inspected and visually problematic spots were manually flagged
and removed. Spots with foreground intensity less than 2.1-fold of
background intensity were considered too weak to be reliable and
also removed. A scaled print-tip intensity-dependent lowess within-
slide normalization was performed on each slide, followed by an
across-slides normalization, using Aroma package version 0.89
[76] run in R project environment (http://cran.r-project.org).
Differential expression and statistical analysis of Seattle data were
done using a linear model method package Limma [77]. The
criteria of the p-value of ,0.05 and expression ratio$2-fold
change were employed for selection of differentially expressed
genes. For Thailand data, statistically significant differences in
gene expression were monitored using the Significance Analysis of
Microarrays (SAM) program [78] and genes showing false
discovery rate (FDR)=0% and expression ratio of $1.5-fold in
both directions were considered differentially expressed. Cluster
analysis was performed using CLUSTER and visualized using
TREEVIEW [79].
Quantitative RT-PCR confirmation
Six of AFDG genes whose ratio of SD/SS was greater than 2 at
24 h of WR99210 exposure were selected for qRT-PCR
validation. These were PFD1120c, PF10_0330, PFC0710w,
PFB0915w, PFB0635w and MAL6P1.231. Three hundred
nanograms of total RNA was primed with Oligo(dT)/random
nanomers mix (at final concentration of 100 ng each/reaction)
and converted to cDNA in 20 ml reactions using AffinityScript
TM
QPCR cDNA synthesis kit (Stratagene) as recommended by the
manufacturer. The reverse transcription reaction was then diluted
with 40 ml of nuclease-free PCR-grade water before using in the
PCR amplification step. Real-time quantitative PCR was
performed on a thermal cycler (DNA Engine, BioRad) equipped
with a detector (Chromo4, BioRad). Primers were designed using
PRIMER3 (http://www-genome.wi.mit.edu/genome_software/
other/primer3.html) and optimized for annealing/extension
temperature, concentration, and single product amplification.
The designed primers are listed in Table S2. Amplifications were
performed in 25 ml final volume, using 12.5 mlo f2 6 BrilliantH
SYBRH Green QPCR Master Mix (Stratagene), 2 ml of the cDNA
template, and 250 nM of each primer. Cycling conditions were:
10 min at 95uC and 40 cycles of 95uC for 15 sec followed by 58uC
for 60 sec. The specificity of the amplifications was monitored by
melting curve analysis and gel electrophoresis. The threshold cycle
of fluorescence (Ct) was determined by Opticon Monitor 3
software (BioRad). The quantity of cDNA for each gene was
normalized to the Seryl-tRNA synthetase (PF07_0073) concentra-
tion in each sample (DCt, Ctgene2CtPF07_0073). Relative gene
expression was calculated by 2
2DDCt method [80], where DDCt is
the ratio of expression of each treatment relative to that of the
trophozoite stage reference. Each PCR experiment was performed
in duplicates with at least three RNA templates prepared from
independent parasite cultures.
Analysis of the DHFR-TS oligos was performed with slight
modifications to the procedure described above. Two hundred
seventy nanograms of total RNA was used per cDNA synthesis
reaction and then diluted with 25 mL of nuclease-free PCR-grade
water. The annealing/extension temperature was reduced to
56uC. Analysis was performed using the Pfaffl method [81] with
each primer pair’s efficiency taken into account. Each experiment
was performed in triplicate and the 24 h time-point was analyzed
in three independent cultures. A representative run is shown and
plotted error bars are the SEM of that run.
Supporting Information
Figure S1 Structures of antifolates used to study changes in
transcript levels in malaria parasites. (A) WR99210 used by the
Seattle lab against sensitive clone Dd2 and resistant clone B1G9
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lab against the sensitive clone TM4/8.2.
Found at: doi:10.1371/journal.ppat.1000214.s001 (0.24 MB TIF)
Figure S2 (A) Representative M-A plot of raw microarray data
from SD24_rep1. In the analysis, data was derived from
microarrays in which RNA from WR99210-treated (Cy5) parasite
and RNA from reference pool (Cy3) control were compared. Raw
data in the form of relative fluorescence intensity were log
transformed and used to calculate M (difference in log intensities)
and A (average log intensity) for each spot on the microarray. Most
spots cluster around the zero line. Red and green spots indicate an
M value of higher and lower than 1, respectively. (B) M-A plot of
scaled print-tip and across slide normalized data. (C) Box-plot
before normalization. (D) Box-plot of scaled print-tip and across
slide normalized data.
Found at: doi:10.1371/journal.ppat.1000214.s002 (0.93 MB TIF)
Figure S3 Log2 (WR99210-treated/reference pool) comparison
between replicates of representative experiment (SD24). (A) Log2
expression ratio comparison between SD24_rep1 and SD24_rep3
(technical replicate). SD24_rep3 is a dye swap experiment of
SD24_rep1. (B) Log2 expression ratio comparison between
SD24_rep1 and SD24_rep2 (biological replicate). (C) Log2
expression ratio comparison between SD24_rep1 and SD24_rep4
(biological replicate). SD24_rep4 is a dye swap experiment of
SD24_rep2. Correlation between replicates demonstrates the high
degree of reproducibility of the data, but biological replicates show
greater variability in part due to stochastic changes in surface gene
expression.
Found at: doi:10.1371/journal.ppat.1000214.s003 (0.46 MB TIF)
Figure S4 Genes whose expression changed permanently in
resistant clone B1G9 comparing to sensitive clone Dd2 (with or
without drug pressure). Each probe was tested for changes in
expression in 4 comparisons (SS vs RS, SD vs RS, SS vs RD, and
SD vs RD) at each time point. Probes were selected against these
comparisons jointly, with multiple testing adjusted p,0.01.
Found at: doi:10.1371/journal.ppat.1000214.s004 (0.47 MB TIF)
Table S1
Found at: doi:10.1371/journal.ppat.1000214.s005 (0.01 MB PDF)
Table S2
Found at: doi:10.1371/journal.ppat.1000214.s006 (0.08 MB PDF)
Table S3
Found at: doi:10.1371/journal.ppat.1000214.s007 (0.03 MB XLS)
Table S4
Found at: doi:10.1371/journal.ppat.1000214.s008 (0.07 MB XLS)
Table S5
Found at: doi:10.1371/journal.ppat.1000214.s009 (0.05 MB XLS)
Table S6
Found at: doi:10.1371/journal.ppat.1000214.s010 (0.05 MB XLS)
Table S7
Found at: doi:10.1371/journal.ppat.1000214.s011 (0.05 MB XLS)
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